JP2024540525A5 - - Google Patents
Info
- Publication number
- JP2024540525A5 JP2024540525A5 JP2024529529A JP2024529529A JP2024540525A5 JP 2024540525 A5 JP2024540525 A5 JP 2024540525A5 JP 2024529529 A JP2024529529 A JP 2024529529A JP 2024529529 A JP2024529529 A JP 2024529529A JP 2024540525 A5 JP2024540525 A5 JP 2024540525A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyrrolo
- hexahydro
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21209168.0 | 2021-11-19 | ||
| EP21209168 | 2021-11-19 | ||
| EP22188185 | 2022-08-02 | ||
| EP22188185.7 | 2022-08-02 | ||
| PCT/EP2022/082174 WO2023088987A1 (en) | 2021-11-19 | 2022-11-17 | Pyridazine derivatives as inhibitors of nlrp3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024540525A JP2024540525A (ja) | 2024-10-31 |
| JP2024540525A5 true JP2024540525A5 (enExample) | 2025-11-17 |
Family
ID=84421135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529529A Pending JP2024540525A (ja) | 2021-11-19 | 2022-11-17 | Ｎｌｒｐ３の阻害剤としてのピリダジン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240308977A1 (enExample) |
| EP (1) | EP4433459A1 (enExample) |
| JP (1) | JP2024540525A (enExample) |
| AR (1) | AR127704A1 (enExample) |
| TW (1) | TW202327603A (enExample) |
| WO (1) | WO2023088987A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| JP2025523930A (ja) * | 2022-07-21 | 2025-07-25 | エフ． ホフマン－ラ ロシュ アーゲー | Ｎｌｒｐ３阻害剤 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| US20260167637A1 (en) * | 2022-11-04 | 2026-06-18 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and use thereof |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法 |
| WO2025229146A1 (en) * | 2024-05-02 | 2025-11-06 | Sanofi | Crystalline form of a pyridazine nlrp3 inhibitor |
| WO2025247338A1 (zh) * | 2024-05-30 | 2025-12-04 | 纽欧申医药(上海)有限公司 | 哒嗪环类化合物、其药物组合物及其应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CN115279739B (zh) * | 2020-03-27 | 2025-07-22 | 尼科治疗有限公司 | 取代哒嗪化合物 |
| EP4289823A4 (en) * | 2021-02-08 | 2025-02-26 | Medshine Discovery Inc. | SUBSTITUTED PYRIDAZINE PHENOL DERIVATIVES |
-
2022
- 2022-11-17 JP JP2024529529A patent/JP2024540525A/ja active Pending
- 2022-11-17 WO PCT/EP2022/082174 patent/WO2023088987A1/en not_active Ceased
- 2022-11-17 EP EP22818338.0A patent/EP4433459A1/en active Pending
- 2022-11-17 AR ARP220103166A patent/AR127704A1/es unknown
- 2022-11-18 TW TW111144209A patent/TW202327603A/zh unknown
-
2024
- 2024-05-16 US US18/666,566 patent/US20240308977A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7210637B2 (ja) | 医学的障害の治療のためのアリール、ヘテロアリール及び複素環式化合物 | |
| CN1289086C (zh) | 抗疟治疗药物的新用途 | |
| CN106061261B (zh) | 治疗化合物的结晶形式及其用途 | |
| AU2022271417A1 (en) | Aerosol pirfenidone and pyridone analog compounds | |
| JP2017528494A (ja) | ｓＧＣ刺激剤 | |
| TW201718553A (zh) | 用於治療醫學病症之醚化合物 | |
| JP2020510015A5 (enExample) | ||
| TW201720438A (zh) | 用於治療醫學病症之化合物 | |
| EP3182974A1 (en) | Heterocyclic amides as rip1 kinase inhibitors as medicaments | |
| TW201718611A (zh) | 用於治療醫學病症之膦酸酯化合物 | |
| CN106459063A (zh) | Mertk‑特异性嘧啶化合物 | |
| JP2007519649A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2007516983A5 (enExample) | ||
| JP2017527605A (ja) | ｓＧＣ刺激剤 | |
| CN113795249A (zh) | 用于治疗补体介导的病症的药物化合物 | |
| JP6695353B2 (ja) | Ｆｇｆｒ４阻害剤としてのホルミル化ｎ−複素環式誘導体 | |
| EP3554503A1 (en) | Inhibitors of bromodomain-containing protein 4 (brd4) | |
| TWI778052B (zh) | 流感病毒複製之抑制劑 | |
| WO2021201201A1 (ja) | 新型コロナウイルス感染症（ｃｏｖｉｄ－１９）の予防または治療剤および医薬組成物 | |
| CN103582644B (zh) | 酞嗪酮-吡咯并嘧啶羧酰胺衍生物 | |
| CA2827299A1 (en) | Liquid propellant-free formulation comprising an antimuscarinic drug | |
| JP2014517021A5 (enExample) | ||
| CN113365617A (zh) | 用于医学疾病治疗的一氧化碳前药 | |
| BR112021008153A2 (pt) | processo para a produção de formas de administração farmacêuticas contendo inibidores de canais task-1 e task-3 e seu uso para a terapia de distúrbios respiratórios |